Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013-2018: a retrospective cohort study. BMC Infect Dis. 2021 Feb 8;21(1):159.
Zurawski DV, Reinhart AA, Alamneh YA, et al. SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2017 Nov 22;61(12):e01239-17.
Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Antimicrobial Susceptibility and Cross-Resistance Patterns among Common Complicated Urinary Tract Infections in U.S. Hospitals, 2013 to 2018. Antimicrob Agents Chemother. 2020 Jul 22;64(8):e00346-20.
Talley AK, Thurston A, Moore G, et al. First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections. Antimicrob Agents Chemother. 2021 Sep 7:AAC0120821.
Stainton SM, Abdelraouf K, Utley L, et al. Assessment of the In Vivo Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model. Antimicrob Agents Chemother. 2018 Jun 26;62(7):e00239-18.
Rex JH, Talbot GH, Goldberger MJ, et al. Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance. Clin Infect Dis. 2017 Jul 1;65(1):141-146.
Unable to find what you were looking for?
Download a complete bibliography from each of our ongoing investigational programs below.